The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

Dr. Sepp-Lorenzino is a recognized leader in drug discovery and development, with a focus on nucleic acid therapeutics, bringing more than three decades of scientific and executive experience ...

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...

Fusobacteria, which are part of the oral microbiome, are suspected of playing a role in cancer progression. Scientists at the ...

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or ...

Japan’s Ono Pharmaceutical and privately-held US firm Jorna Therapeutics are ready to go in a research collaboration ...

About Rona TherapeuticsRona Therapeutics is a global leader in nucleic acid therapeutics discovery and development, specializing in the treatment of cardiometabolic and neurological diseases.